Health Trials

Metastatic Castration-resistant Prostate Neoplasms

2

Review clinical trials related to Metastatic Castration-resistant Prostate Neoplasms. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).

Participants needed: 663
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: Janssen Research & Development, LLCUpdated: Jun 5, 2026Locations: 168
Eligibility criteria

Histologically confirmed adenocarcinoma of the prostate [+9]

Venous thromboembolic events within 1 month prior to the first dose of study tre... [+4]

Read more
Status: Recruiting

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).

Participants needed: 300
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: Janssen Research & Development, LLCUpdated: Jun 5, 2026Locations: 15
Eligibility criteria

Part 1 A-G, 1I, 1J, and 1K (all combination treatments) and Parts 2B-C (cabazita... [+4]

Active autoimmune disease within the 12 months prior to signing consent that req... [+4]

Read more